QURE Stock Summary and Trading Ideas (Uniqure N.V. - | NASDAQ:QURE)

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Uniqure N.V. - trades on the NASDAQ stock market under the symbol QURE.

As of January 9, 2026, QURE stock price climbed to $25.32 with 4,005,519 million shares trading.

QURE has a beta of 1.85, meaning it tends to be more sensitive to market movements. QURE has a correlation of 0.03 to the broad based SPY ETF.

QURE has a market cap of $1.58 billion. This is considered a Small Cap stock.

Last quarter Uniqure N.V. - reported $4 million in Revenue and -$1.38 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.59.

In the last 3 years, QURE traded as high as $71.50 and as low as $3.73.

The top ETF exchange traded funds that QURE belongs to (by Net Assets): XBI, VXF, IBB, SCHA, LABU.

QURE has outperformed the market in the last year with a price return of +59.0% while the SPY ETF gained +19.0%. However, in the short term, QURE had mixed performance relative to the market. It has underperformed in the last 3 months, returning -60.2% vs +3.7% return in SPY. But in the last 2 weeks, QURE shares have fared better than the market returning +2.1% compared to SPY +0.5%.

QURE support price is $22.10 and resistance is $24.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QURE shares will trade within this expected range on the day.